Table 1 Baseline characteristics
AIT (n = 26) | LED + AIT (n = 29) | p | |
|---|---|---|---|
Male | 22 (85%) | 21 (72%) | 0.34 |
Age | 62.3 (5.7) | 63.8 (6.7) | 0.38 |
VO2peakffm (mL/kg ffm0.67/min) | 124 (24) | 126 (25) | 0.83 |
VO2peakbw (mL/kg/min) | 20.8 (4.9) | 20.6 (5.0) | 0.85 |
Body weight (kg) | 96.2 (13.8) | 95.5 (10.7) | 0.85 |
Body mass index (kg/m2) | 31.5 (29.6; 33.5) | 31.3 (29.9; 33.7) | 0.85 |
Body fat mass (kg) | 32.6 (7.6) | 34.6 (8.0) | 0.36 |
Waist circumference (cm) | 110 (10) | 108 (7) | 0.36 |
Hip circumference (cm) | 111 (8) | 110 (7) | 0.80 |
Systolic blood pressure (mmHg) | 126 (13) | 127 (15) | 0.78 |
Diastolic blood pressure (mmHg) | 74 (9.2) | 71 (7.7) | 0.18 |
Total cholesterol (mmol/L) | 4.3 (0.8) | 4.1 (0.7) | 0.23 |
Left ventricular ejection fraction (%) | 53 (8) | 53 (7) | 0.97 |
Pre-diabetes | 21 (81%) | 25 (86%) | 0.59 |
Ischaemic aetiology and treatment | |||
Myocardial infarction | 8 (31%) | 22 (76%) | < 0.001 |
Percutaneous coronary intervention | 17 (65%) | 23 (79%) | 0.25 |
Coronary artery bypass graft | 6 (23%) | 6 (21%) | 0.83 |
Prior cardiac rehabilitation | 24 (92%) | 21 (72%) | 0.06 |
CCS-class | |||
0 | 21 (81%) | 23 (79%) | |
I | 5 (19%) | 6 (21%) | 0.89 |
NYHA-class | |||
I | 21 (81%) | 21 (72%) | |
II | 5 (19%) | 7 (24%) | 0.87 |
III | 0 (0%) | 1 (3%) | |
Medication | |||
ACE-I/ARB | 15 (58%) | 21 (72%) | 0.57 |
Acetylsalicylic acid | 23 (88%) | 26 (90%) | 1.00 |
Beta blocker | 12 (46%) | 16 (55%) | 0.50 |
Calcium antagonist | 6 (23%) | 10 (34%) | 0.39 |
Statin | 25 (96%) | 28 (97%) | 1.00 |
Other cholesterol-lowering drug | 5 (19%) | 2 (7%) | 0.24 |